FDA Approves Adcetris / brentuximab vedotin + lenalidomide & rituximab in relapsed or refractory LBCL: Could This Change Standard Care? Lymphoma 2 Mins Read
2024 Update on Lymphoma Treatment: Navigating the Latest Advances – Elizabeth Brem, MD [38 Slides] Hodgkin Lymphoma 4 Mins Read
FDA Grants Accelerated Approval to Zanubrutinib (Brukinsa) for Relapsed or Refractory Follicular Lymphoma Lymphoma 2 Mins Read
